Meningioma

This case highlights the limits of imaging-based diagnosis in dural-based masses and supports systematic STAT6 immunohistochemistry to establish SFT diagnosis, guide counseling on recurrence risk, and plan surveillance. This case report was prepared according to SCARE 2025 guidelines.

Planned, selective resection of giant NF2-related skull base collision tumors yielded a median reoperation-free interval of 6.1 years and maintained functional independence in a young, heavily pretreated population, supporting its feasibility as a longitudinal management strategy.

DMPA-associated meningiomas represent a recognizable phenotype within the broader NF2-wildtype/TRAF7-enriched spectrum of benign meningiomas, characterized by chromosomal stability, a shared methylation profile, tumor multiplicity, and regression or stabilization following DMPA cessation. While derived from a small single-institution cohort, these findings provide a molecular framework for understanding progestin-associated meningioma biology, re-interpreting epidemiologic literature, and informing population-level risk stratification.

Clinicians should remain vigilant for "imaging paradoxes" - where an unusually aggressive clinical course contradicts typical radiological features. In such atypical cases, an expanded immunohistochemical panel including CD68 and CD163 is essential to avoid diagnostic delays and ensure accurate identification.

Tissue miR-221, miR-143, and miR-22 are consistently downregulated in intracranial meningioma and demonstrate clinically meaningful diagnostic performance, with miR-221 showing the highest discriminatory accuracy. These findings support the potential integration of miRNA assays into tissue-based diagnostics and warrant multicenter validation to refine cut-off values and evaluate prognostic utility.

Overall, this work establishes dacinostat as a promising radiosensitiser that compromises DNA repair fidelity and moduflates SUMOylation-associated pathways, thereby enhancing efficacy in treatment-resistant meningiomas. These findings provide a compelling preclinical basis to advance dacinostat into clinical assessment for the management of aggressive meningioma.

While surgical gross complete resection is the gold standard, significant postoperative tumor bed edema complicates perioperative treatment and may necessitate additional therapies. Identifying SM as a unique clinical entity is essential for diagnosis, prognosis, and therapeutic approaches.

Perineurioma-like, EMA-positive calvarial neoplasms are a rare group of spindle cell tumours for which no local recurrence or distant metastasis has been documented to date, although they do show a propensity for progressive growth. Recognition of their distinctive clinicopathological and radiological features is important for accurate diagnostic classification and appropriate patient management.

Combined surgical revision and targeted prolonged antibiotics are essential. Longitudinal DWI and ADC quantification serve as objective imaging biomarkers for monitoring abscess activity and treatment response.

These results support a role for VEGF signaling and macrophage-mediated microenvironmental changes in edema and cystic growth of NF2-SWN SE. The observed clinical response to AXITINIB in an index patient suggests that new combinations of anti-angiogenic therapies may represent a promising early targeted approach.

The coexistence of GBM and meningioma appears mostly coincidental, driven by distinct molecular pathways rather than a common progenitor. Despite the benign nature of the associated meningioma, prognosis is dictated by the aggressive GBM component. Early surgical intervention and modern adjuvant therapy remain essential for optimizing survival in these complex cases.

P3, N=136, Not yet recruiting, Shanghai Runshi Pharmaceutical Technology Co., Ltd